Abstract Number: PB1211
Meeting: ISTH 2021 Congress
Background: Clinical management and treatment of cancer-associated thrombosis (CAT) are important challenges for physicians that deal with venous thromboembolism (VTE).
Aims: To evaluate the profile and management of patients with CAT in a private hospital in Salvador, participating in the RIETE registry.
Methods: Consecutive patients from 5/2018 to 12/2019 were evaluated and differences between CAT patients and other-VTE patients were compared.
Results: Of the 95 patients, 67.4% were women, the mean age 53.29 years (± 18.99) and, higher for CAT, 65.82 (±15.63) than for other-VTE, 49.52 (±18.36), p<0.001). There were 64.2% PE, 17.9% DVT/PE and 17.9% DVT, with high rates of PE between CAT and other-VTE and there was no incidental PE. The primary cancer site was breast 27.3%, prostate 18.2% and lung 13.6%. Among the risk factors for CAT, 13.6% used hormones, 18.2% history of VTE, 22.7% had obesity, 13.6% immobility >4 days, 9.1% smoking, 4.5% recent travel>6 hours, none had family history of VTE; hypertension was more frequent in CAT than other-VTE: 63.6% vs. 39.7%, p=0.05. The mean length-of-stay was 9,13±5.99 days, being shorter for CAT (7.77±6.52 days). The initial choice of anticoagulant for all cancer patients was enoxaparin 100%; the choice for maintenance therapy after discharge for this group was rivaroxaban 41.2% and apixaban 41.2%. There were some differences between the choice of anticoagulants for CAT and other VTE, however, both enoxaparin and rivaroxaban were the most used in both groups and in both situations, respectively.
|N (%)||N (%)||N (%)|
|Anticoagulant of maintenance|
|Enoxaparin||3 (3.9)||2 (3.3)||1 (5.9)||0.33|
|Warfarin||25 (19.5)||14 (23.3)||1 (5.9)|
|Rivaroxaban||36 (46.8)||29 (48.3)||7 (41.2)|
|Apixaban||20 (26.0)||13 (21.7)||7 (41.2)|
|Edoxaban||3 (3.9)||2 (3.3)||1 (5.9)|
|Total||95 (100)||73 (76.8)||22 (23.2)||–|
|Primary site of cancer||Total = 22 – n (%)|
Conclusions: This cohort in the Brazil’s Northeast had more women with CAT, high rates of PE and other important risk factors such as hormone use and obesity. Enoxaparin (low molecular weight heparin) was still the main choice for initial treatment, but direct oral anticoagulants (DOACs) were more common in the treatment of cancer patients.
To cite this abstract in AMA style:de Abreu Couto Vieira J, Santos de Oliveira Júnior R, Cavalcanti Rocha AT. Differences of Profile and Management of Cancer-associated Thrombosis in a RIETE’s Hospital in Brazil [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/differences-of-profile-and-management-of-cancer-associated-thrombosis-in-a-rietes-hospital-in-brazil/. Accessed August 15, 2022.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/differences-of-profile-and-management-of-cancer-associated-thrombosis-in-a-rietes-hospital-in-brazil/